Emerging Markets, Far East Asia & Australasia 

Listen to the latest market access and pricing developments in Africa, Latin America, Middle East, Far East Asia and Australia

THE FAR EAST, Thursday 24 September 2020

Registration & refreshments

Morning Plenary

Erik Van Den Berg
09:00

Innovation in industry and practical considerations for biotechs

Ion Agirrezabal
09:20

Trends in modelling approaches for successful reimbursement of ATMPs

Bharat Tewarie
09:40

Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

10:20

Speed Networking

10:40

Morning refreshments

David Thompson
11:20

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Thomas Mueller
11:40

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

round tables
12:00

Roundtables

Roundtable 10: Accelerating access to treatments for rare diseases
Kate Adcock

Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.

Roundtable 11: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter

Michael Schroter, Partner, Viopas Partners

Roundtable 12: Exploring reimbursement and healthcare systems across the Middle East
Rita Shorjian

Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie

Roundtable 14: Indication based pricing- where are we?
David Catterick

David Catterick, Head Of Market Access Uk, Amgen

Roundtable 15: Access and HTA considerations for Turkey, Kazakhstan and Ukraine
Oleksandr Topachevskyi

Oleksandr Topachevskyi, Essential Medicines List Committee Member, Ministry of Health of Ukraine

Roundtable 16: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster

Douglas Foerster, Head Market Access, Santhera Pharmaceuticals

Roundtable 17: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay

Sagie Pillay, Chief Operating Officer, Wits Health Consortium

Roundtable 18: Exploring innovative reimbursement and payment models for orphan drugs
Sebastian Soluch

Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc

Roundtable 19: Branded combo-pricing: Where to next?
Yves Samel

Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer

Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos

Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie

Roundtable 20:Achieving greater collaboration with HTAs: Insights from EUnetHTA & Industry
Francesca Cook

Francesca Cook, Senior Director, Global Head Of Pricing And Market Access, Regenxbio

Roundtable 21: Developments in pricing and patient access for speciality treatments
Keith White

Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals

Roundtable 22: Virtual approaches for real-world research
Erwin De Cock

Erwin De Cock, Principal, Late Stage, Syneos Health

Roundtable 23: Pricing Strategy – What to Do and When?
Andreia Ribeiro

Andreia Ribeiro, Director, Lifescience Dynamics Ltd

Roundtable 24: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan

Gomathi Kaliappan, Global Market Access - Health Systems Strategy, Value Recognition, Roche

Roundtable 25: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu

Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)

Roundtable 26: Game-changing policies for game-changing innovations: what regulatory changes to ensure the development, diffusion and sustainability of new technologies
Gerard De Pouvourville

Gerard De Pouvourville, Professor And Chairman, Health Economics And Management, ESSEC Business School

Roundtable 27: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich

Adam Plich, Managing Director, Plich Advisory

Roundtable 28: Exploring access and pricing challenges for low to middle income countries
Giovanny Leon

Giovanny Leon, P&Ma Director, Novartis AG

Roundtable 29: Access and pricing considerations for CAR-T development
Nuno Prego Ramos

Nuno Prego Ramos, Chief Executive Officer, CellmAbs

Roundtable 2: How do you include the patient perspective in a outcomes-based contract?
Nico Mros

Nico Mros, Chief Operating Officer, Lyfegen HealthTech AG

Roundtable 30: Exploring commercial strategies for orphan drugs in the public healthcare system of Argentina
Marcelo Sal

Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics

Roundtable 31: Challenges associated with communicating the value of Cell & Gene Therapies
Anushini Muthutantri

Anushini Muthutantri, Director, Evidence, Value And Access, Consulting at McCann Health

Roundtable 33: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther

Alan Crowther, General Manager, EVERSANA

Roundtable 34: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Yannick Loonus

Yannick Loonus, Chief Sales Officer, Semalytix GmbH

Roundtable 35: Patient based generated evidence
David Elvira

David Elvira, Heads Eu Public Affairs, Sanofi

Roundtable 36: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Jost Leemhuis

Jost Leemhuis, Head Of Safety Science, Roche

Roundtable 37: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE
Josie Godfrey

Josie Godfrey, Director, JG Zebra Consulting

Roundtable 7: Achieving positive reimbursement negotiations
Hassan Bruneo

Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh

Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach
Nadia Bodkin

Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement

Roundtable 9: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate

Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara

12:50

Networking Lunch and Poster Viewing

THE FAR EAST & AUSTRALASIA

East Asia, Australia & New Zealand

Amy Wang
THE FAR EAST
14:35

Breaking down the ‘Great Wall’: do the evolving market access policy dynamics in China represent the next big opportunity of Pharma?

Marijn Verhoef
THE FAR EAST
14:55

Bringing accessibility and affordability to scale in the next decade

16:20

Afternoon Refreshment Break

17:55

Close of conference and networking drinks reception

last published: 06/Jul/20 13:55

HTA, Thursday 24 September 2020

Registration & refreshments

Morning Plenary

Erik Van Den Berg
09:00

Innovation in industry and practical considerations for biotechs

Ion Agirrezabal
09:20

Trends in modelling approaches for successful reimbursement of ATMPs

Bharat Tewarie
09:40

Unleash the Algorithms: Critical Success Factors to Reinvent Our Role in Delivering Patient Value

10:20

Speed Networking

10:40

Morning refreshments

David Thompson
11:20

Virtual Research: What it Is & What it’s Doing in the Real-World Setting

Thomas Mueller
11:40

Orphan Drugs, Gene Therapies, Post-Marketing-Data: Latest developments in German legal framework for drug assessment and reimbursement

round tables
12:00

Roundtables

Roundtable 10: Accelerating access to treatments for rare diseases
Kate Adcock

Kate Adcock, Director Of Research And Innovation, The Muscular Dystrophy U.K.

Roundtable 11: Does pricing innovative drugs fairly improve your bottomline?
Michael Schroter

Michael Schroter, Partner, Viopas Partners

Roundtable 12: Exploring reimbursement and healthcare systems across the Middle East
Rita Shorjian

Rita Shorjian, Market Access Head - Near East And North West Africa, AbbVie

Roundtable 14: Indication based pricing- where are we?
David Catterick

David Catterick, Head Of Market Access Uk, Amgen

Roundtable 15: Access and HTA considerations for Turkey, Kazakhstan and Ukraine
Oleksandr Topachevskyi

Oleksandr Topachevskyi, Essential Medicines List Committee Member, Ministry of Health of Ukraine

Roundtable 16: Exploring the value from repurposing drugs: Who Benefits?
Douglas Foerster

Douglas Foerster, Head Market Access, Santhera Pharmaceuticals

Roundtable 17: Exploring challenges and opportunities across Africa on achieving new affordable strategies for Universal Health Coverage
Sagie Pillay

Sagie Pillay, Chief Operating Officer, Wits Health Consortium

Roundtable 18: Exploring innovative reimbursement and payment models for orphan drugs
Sebastian Soluch

Sebastian Soluch, Head Of Market Access And Pricing, Europe, Stemline Therapeutics Inc

Roundtable 19: Branded combo-pricing: Where to next?
Yves Samel

Yves Samel, Market Access Strategy Leader And Global Pricing Manager, Bayer

Roundtable 1: Efficacy to Effectiveness - E2E – translating the promise of clinical trials to the real world
Chris Pashos

Chris Pashos, Former Vice President Of Global Evidence Strategy, AbbVie

Roundtable 20:Achieving greater collaboration with HTAs: Insights from EUnetHTA & Industry
Francesca Cook

Francesca Cook, Senior Director, Global Head Of Pricing And Market Access, Regenxbio

Roundtable 21: Developments in pricing and patient access for speciality treatments
Keith White

Keith White, Vice President And Head, Global Market Access, Corbus Pharmaceuticals

Roundtable 22: Virtual approaches for real-world research
Erwin De Cock

Erwin De Cock, Principal, Late Stage, Syneos Health

Roundtable 23: Pricing Strategy – What to Do and When?
Andreia Ribeiro

Andreia Ribeiro, Director, Lifescience Dynamics Ltd

Roundtable 24: Exploring reimbursement models: Working with external stakeholders to improve outcomes
Gomathi Kaliappan

Gomathi Kaliappan, Global Market Access - Health Systems Strategy, Value Recognition, Roche

Roundtable 25: Oncology drug market: a high-growth, high-price therapeutic area
Elena Lungu

Elena Lungu, Manager Of Policy Development, Government of Canada (Canada)

Roundtable 26: Game-changing policies for game-changing innovations: what regulatory changes to ensure the development, diffusion and sustainability of new technologies
Gerard De Pouvourville

Gerard De Pouvourville, Professor And Chairman, Health Economics And Management, ESSEC Business School

Roundtable 27: Pricing Competition from Launch to Loss of Exclusivity
Adam Plich

Adam Plich, Managing Director, Plich Advisory

Roundtable 28: Exploring access and pricing challenges for low to middle income countries
Giovanny Leon

Giovanny Leon, P&Ma Director, Novartis AG

Roundtable 29: Access and pricing considerations for CAR-T development
Nuno Prego Ramos

Nuno Prego Ramos, Chief Executive Officer, CellmAbs

Roundtable 2: How do you include the patient perspective in a outcomes-based contract?
Nico Mros

Nico Mros, Chief Operating Officer, Lyfegen HealthTech AG

Roundtable 30: Exploring commercial strategies for orphan drugs in the public healthcare system of Argentina
Marcelo Sal

Marcelo Sal, Head of Market Access and Pricing, Argentina, PTC Therapeutics

Roundtable 31: Challenges associated with communicating the value of Cell & Gene Therapies
Anushini Muthutantri

Anushini Muthutantri, Director, Evidence, Value And Access, Consulting at McCann Health

Roundtable 33: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther

Alan Crowther, General Manager, EVERSANA

Roundtable 34: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Yannick Loonus

Yannick Loonus, Chief Sales Officer, Semalytix GmbH

Roundtable 35: Patient based generated evidence
David Elvira

David Elvira, Heads Eu Public Affairs, Sanofi

Roundtable 36: Achieving greater collaboration amongst payers, HTAs, pharma and patients to improve outcomes
Jost Leemhuis

Jost Leemhuis, Head Of Safety Science, Roche

Roundtable 37: Advanced Therapies: The role of registries in convincing payers about long-term effects
Alexander Natz

Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)

Roundtable 6: A tale of two diseases: how orphan drugs can navigate NICE
Josie Godfrey

Josie Godfrey, Director, JG Zebra Consulting

Roundtable 7: Achieving positive reimbursement negotiations
Hassan Bruneo

Hassan Bruneo, Associate Director, Alnylam Switzerland Gmbh

Roundtable 8: The development of a patient advocate – How to find experienced and qualified patient advocates- The Continual Professional Development approach
Nadia Bodkin

Nadia Bodkin, Rare Disease Advocacy Professional, Rare Advocacy Movement

Roundtable 9: Using Health Economic Studies to Support Access and Value
Fabrizio Gianfrate

Fabrizio Gianfrate, Professor Of Health Economics, Market Access Advisor, Universities of Rome and Ferrara

12:50

Networking Lunch and Poster Viewing

HTA

Innovation in HTA

Dapo Ogunbayo
HTA
14:15

Horizon scanning in the HTA process; helping to facilitate UK market access

Rosemary Jose
HTA
14:35

EUnetHTA Joint Assessments and Implications for the Industry

Gwilym Thompson
HTA
14:55

The use of frameworks to support HTA processes

Gwilym Thompson, Director, Markets, Health Economics And Outcomes Research, Bristol-Myers Squibb

HTA

Stakeholder Engagement and Integrating Evidence

Goedele Van Haasteren
HTA
15:20

HTA for Switzerland and stakeholder engagement

Goedele Van Haasteren, Hta Specialist, Swiss Federal Office of Public Health
Mario Ouwens
HTA
16:00

The DIVE framework: how to incorporate all information into your estimation process: Direct evidence, Indirect evidence, validation and external information incorporation?

16:20

Afternoon Refreshment Break

17:55

Close of conference and networking drinks reception

last published: 06/Jul/20 13:55

THE FAR EAST, Friday 25 September 2020

Morning Plenary

Panel discussion
10:20

Morning refreshments

round tables
11:00

Roundtables

Roundtable 10: Real world data and its utility in HTA decisions
Madhusudan Kabra

Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical

Roundtable 11: Market Access and pricing considerations for Spain
Carme Pinyol

Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre

Roundtable 12: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan

Niri Bhimsan, Head - Health Technology Assessment, Discovery Health

Roundtable 13: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell

Warren Cowell, Director Market Access UK, Shionogi

Roundtable 14: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver

Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.

Roundtable 15: Reserved for Lifescience Dynamics
Roundtable 16: Opportunities & Challenges for Collection of RWD in Early Access Programs (EAPs)
Alastair Macdonald

Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health

Roundtable 17: Exploring repurposed products for rare diseases
Amer Omar

Amer Omar, Senior Director, Lupin

Roundtable 19: Modelling the value of digital health innovations
Trishal Boodhna

Trishal Boodhna, Senior Health Economist, Consulting at McCann Health

Roundtable 20: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther

Alan Crowther, General Manager, EVERSANA

Roundtable 21: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Yannick Loonus

Yannick Loonus, Chief Sales Officer, Semalytix GmbH

Roundtable 22: Pricing developments in the US and the wider impact
Nicki Catterick

Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group

Roundtable 23: Understanding Business Challenges of Shifting IV drugs to SC to Enable Self-delivery
Marie-Liesse Le Corfec

Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems

Roundtable 24: Innovative pricing of rare disease medicines – what is pharma’s model for the 2020s
Simon Shohet

Simon Shohet, Head Of International Market Access, Amicus Therapeutics

Roundtable 25: Exploring value-added medicines
Maja Sercic

Maja Sercic, Policy&Science Manager, Medicines for Europe

Roundtable 3: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert

Sue Naeyaert, Advisor, Independent

Roundtable 4: Accelerating Access to treatments for Rare Diseases
Rob De With

Rob De With, Head of Rare Diseases for Europe and Canada, Takeda

Roundtable 5: How to establish a market access department from scratch?
Michael Muller

Michael Muller, Head Of Market Access, Western Europe, Sun Pharma

Roundtable 7: Exploring the international reference pricing landscape
Tanya Aiden

Tanya Aiden, Global Products Lead, BIOCAD

Roundtable 8: Achieving better alignment amongst stakeholders regarding definitions and concepts of value in diagnostics
Benjamin Gannon

Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics

Roundtable 9: Market access, Pricing, Payer & HTA developments for the Nordic Region
Sune Lindgaard

Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark

Roundtables 2: Risk-sharing arrangements: Are they improving patient access to new medicines?
Catarina Lopes Pereira

Catarina Lopes Pereira, Global Market Access Manager, Medac

13:05

Networking Lunch and Poster Viewing

15:10

Afternoon Refreshments

16:45

Close of conference

last published: 06/Jul/20 13:55

HTA, Friday 25 September 2020

Morning Plenary

Panel discussion
10:20

Morning refreshments

round tables
11:00

Roundtables

Roundtable 10: Real world data and its utility in HTA decisions
Madhusudan Kabra

Madhusudan Kabra, Director, Evidence Generation, Otsuka Pharmaceutical

Roundtable 11: Market Access and pricing considerations for Spain
Carme Pinyol

Carme Pinyol, Head Of Pricing And Market Access Southern Europe, Pierre Fabre

Roundtable 12: Exploring High Cost Novelty Medicine Access and HTA in South Africa
Niri Bhimsan

Niri Bhimsan, Head - Health Technology Assessment, Discovery Health

Roundtable 13: Exploring HTA requirements and novel payment methods for anti-biotics
Warren Cowell

Warren Cowell, Director Market Access UK, Shionogi

Roundtable 14: Achieving the best outcomes when negotiating managed entry agreements
Inneke Van De Vijver

Inneke Van De Vijver, Strategic Advisor - Reimbursement Pharmaceuticals, N.I.H.D.I.

Roundtable 15: Reserved for Lifescience Dynamics
Roundtable 16: Opportunities & Challenges for Collection of RWD in Early Access Programs (EAPs)
Alastair Macdonald

Alastair Macdonald, Senior Vice President Of Real World And Late Phase, Syneos Health

Roundtable 17: Exploring repurposed products for rare diseases
Amer Omar

Amer Omar, Senior Director, Lupin

Roundtable 19: Modelling the value of digital health innovations
Trishal Boodhna

Trishal Boodhna, Senior Health Economist, Consulting at McCann Health

Roundtable 20: The Modeling Impact of Policy Decisions on Pricing
Alan Crowther

Alan Crowther, General Manager, EVERSANA

Roundtable 21: What if you could listen to 1,000,000,000 authentic patient voices? Turning real-world conversations into evidence
Yannick Loonus

Yannick Loonus, Chief Sales Officer, Semalytix GmbH

Roundtable 22: Pricing developments in the US and the wider impact
Nicki Catterick

Nicki Catterick, Senior Director, Global Market Access And Pricing, Merck Group

Roundtable 23: Understanding Business Challenges of Shifting IV drugs to SC to Enable Self-delivery
Marie-Liesse Le Corfec

Marie-Liesse Le Corfec, Global Portfolio Marketing Head, Ps, B.D. Pharmaceuticals Systems

Roundtable 24: Innovative pricing of rare disease medicines – what is pharma’s model for the 2020s
Simon Shohet

Simon Shohet, Head Of International Market Access, Amicus Therapeutics

Roundtable 25: Exploring value-added medicines
Maja Sercic

Maja Sercic, Policy&Science Manager, Medicines for Europe

Roundtable 3: Exploring Biosimilars in the USA and Europe – latest developments
Sue Naeyaert

Sue Naeyaert, Advisor, Independent

Roundtable 4: Accelerating Access to treatments for Rare Diseases
Rob De With

Rob De With, Head of Rare Diseases for Europe and Canada, Takeda

Roundtable 5: How to establish a market access department from scratch?
Michael Muller

Michael Muller, Head Of Market Access, Western Europe, Sun Pharma

Roundtable 7: Exploring the international reference pricing landscape
Tanya Aiden

Tanya Aiden, Global Products Lead, BIOCAD

Roundtable 8: Achieving better alignment amongst stakeholders regarding definitions and concepts of value in diagnostics
Benjamin Gannon

Benjamin Gannon, Vice President International Access, Policy And Advocacy, Myriad genetics

Roundtable 9: Market access, Pricing, Payer & HTA developments for the Nordic Region
Sune Lindgaard

Sune Lindgaard, Chief Of Business Intelligence, Amgros, Denmark

Roundtables 2: Risk-sharing arrangements: Are they improving patient access to new medicines?
Catarina Lopes Pereira

Catarina Lopes Pereira, Global Market Access Manager, Medac

13:05

Networking Lunch and Poster Viewing

15:10

Afternoon Refreshments

16:45

Close of conference

last published: 06/Jul/20 13:55

Contact us

To sponsor or exhibit:
Edmond Rama
+44 (0)207 092 1052

edmond.rama@terrapinn.com

To speak:
Chris Shanks
+44 (0)207 092 1151

chris.shanks@terrapinn.com